IL308853A - A combination of therapy that includes a MAT II inhibitor and a type II fermet inhibitor - Google Patents

A combination of therapy that includes a MAT II inhibitor and a type II fermet inhibitor

Info

Publication number
IL308853A
IL308853A IL308853A IL30885323A IL308853A IL 308853 A IL308853 A IL 308853A IL 308853 A IL308853 A IL 308853A IL 30885323 A IL30885323 A IL 30885323A IL 308853 A IL308853 A IL 308853A
Authority
IL
Israel
Prior art keywords
methyl
amino
trifluoromethyl
inhibitor
pyridinyl
Prior art date
Application number
IL308853A
Other languages
English (en)
Hebrew (he)
Inventor
Michael Patrick Dillon
Claire L Neilan
Marcus Michael Fischer
Kimberline Yang Gerrick
Original Assignee
Ideaya Biosciences Inc
Michael Patrick Dillon
Claire L Neilan
Marcus Michael Fischer
Kimberline Yang Gerrick
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ideaya Biosciences Inc, Michael Patrick Dillon, Claire L Neilan, Marcus Michael Fischer, Kimberline Yang Gerrick filed Critical Ideaya Biosciences Inc
Publication of IL308853A publication Critical patent/IL308853A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50Pyridazines; Hydrogenated pyridazines
    • A61K31/502Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
IL308853A 2021-06-02 2022-06-01 A combination of therapy that includes a MAT II inhibitor and a type II fermet inhibitor IL308853A (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202163196008P 2021-06-02 2021-06-02
US202263362438P 2022-04-04 2022-04-04
US202263364360P 2022-05-09 2022-05-09
PCT/US2022/072693 WO2022256806A1 (en) 2021-06-02 2022-06-01 Combination therapy comprising a mat2a inhibitor and a type ii prmt inhibitor

Publications (1)

Publication Number Publication Date
IL308853A true IL308853A (en) 2024-01-01

Family

ID=84323602

Family Applications (1)

Application Number Title Priority Date Filing Date
IL308853A IL308853A (en) 2021-06-02 2022-06-01 A combination of therapy that includes a MAT II inhibitor and a type II fermet inhibitor

Country Status (11)

Country Link
US (2) US20240108626A1 (enExample)
EP (1) EP4347569A4 (enExample)
JP (1) JP2024521920A (enExample)
KR (1) KR20240019172A (enExample)
AU (1) AU2022287057A1 (enExample)
BR (1) BR112023025360A2 (enExample)
CA (1) CA3220160A1 (enExample)
CL (1) CL2023003603A1 (enExample)
IL (1) IL308853A (enExample)
MX (1) MX2023014405A (enExample)
WO (1) WO2022256806A1 (enExample)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11077101B1 (en) 2018-07-18 2021-08-03 Tango Therapeutics, Inc. Compounds and methods of use
MX2021006841A (es) 2018-12-10 2021-07-02 Ideaya Biosciences Inc Derivados de 2-oxoquinazolina como inhibidores de metionina adenosiltransferasa 2?.
WO2021086879A1 (en) 2019-10-28 2021-05-06 Tango Therapeutics, Inc. Compounds and methods of use
EP4188920A1 (en) 2020-07-31 2023-06-07 Tango Therapeutics, Inc. Piperidin-1-yl-n-pyrydine-3-yl-2-oxoacetamide derivatives useful for the treatment of mtap-deficient and/or mta-accumulating cancers
KR20240019172A (ko) * 2021-06-02 2024-02-14 아이디어야 바이오사이언시스 인코포레이티드 Mat2a 억제제 및 유형 ii prmt 억제제를 포함하는 병용 요법
EP4458812A1 (en) * 2021-12-27 2024-11-06 Medshine Discovery Inc. Pyrazole-1(2h)-phthalazinone compound and application thereof
US20250171432A1 (en) * 2022-01-26 2025-05-29 Tango Therapeutics, Inc. Compounds and methods of use
WO2023202626A1 (zh) * 2022-04-22 2023-10-26 北京望实智慧科技有限公司 稠和哒嗪酮化合物作为prmt5抑制剂
WO2023246873A1 (zh) * 2022-06-23 2023-12-28 南京明德新药研发有限公司 氨基取代的杂芳基衍生物及其应用
EP4549442A1 (en) * 2022-07-01 2025-05-07 Cytosinlab Therapeutics Co., Ltd. Prmt5 inhibitors and use thereof
WO2024027703A1 (zh) * 2022-08-02 2024-02-08 上海艾力斯医药科技股份有限公司 一种prmt5抑制剂、其制备方法及应用
JP2026508792A (ja) * 2022-10-25 2026-03-13 タンゴ セラピューティクス, インコーポレイテッド 結晶形態、医薬組成物、及びその使用方法
CN120265615A (zh) * 2022-11-29 2025-07-04 正大天晴药业集团股份有限公司 含有二氢酞嗪的化合物
WO2024118943A2 (en) * 2022-11-30 2024-06-06 Ideaya Biosciences, Inc. Combination therapy comprising a mat2a inhibitor and a prmt5 inhibitor
TW202440126A (zh) * 2022-11-30 2024-10-16 美商安進公司 利用mta協作的prmt5抑制劑和mat2a抑制劑之癌症治療
EP4644389A1 (en) * 2022-12-30 2025-11-05 Suzhou Puhe Biopharma Co., Ltd. Prmt5-mta inhibitor
EP4653435A1 (en) * 2023-01-17 2025-11-26 Suzhou Puhe Biopharma Co., Ltd. Prmt5-mta inhibitor
EP4694892A1 (en) * 2023-04-13 2026-02-18 Ideaya Biosciences, Inc. Combination therapy comprising a mat2a inhibitor and a topoisomerase inhibitor, a splicing inhibitor sulfonamide, or a kif18 inhibitor
CN121175299A (zh) * 2023-04-28 2025-12-19 智擎生技制药股份有限公司 Mta协同性prmt5抑制剂
CN121712509A (zh) 2023-05-04 2026-03-20 锐新医药公司 用于ras相关疾病或病症的组合疗法
CN116283800B (zh) * 2023-05-16 2023-07-18 英矽智能科技(上海)有限公司 氧代喹唑啉类化合物及其应用
US20250049810A1 (en) 2023-08-07 2025-02-13 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
KR20260049253A (ko) * 2023-08-08 2026-04-13 미라티 테라퓨틱스, 인크. 악성 말초 신경초 종양을 치료하는 방법 및 조성물
IL327063A (en) * 2023-09-15 2026-05-01 Ideaya Biosciences Inc Methods for treating MAT2A-related diseases
CN121866246A (zh) * 2023-09-20 2026-04-14 西藏海思科制药有限公司 一种含氰基的杂环化合物及其用途
IL327306A (en) 2023-10-12 2026-05-01 Revolution Medicines Inc Macrocyclic RAS inhibitors
CN121889382A (zh) * 2023-11-08 2026-04-17 北京泰德制药股份有限公司 Prmt5抑制剂及其制备方法
TW202532070A (zh) * 2023-12-01 2025-08-16 大陸商上海翰森生物醫藥科技有限公司 四並環類衍生物抑制劑、其製備方法和應用
WO2025157286A1 (zh) * 2024-01-26 2025-07-31 上海湃隆生物科技有限公司 包含prmt5抑制剂和mat2a抑制剂的药物组合物
WO2025166308A1 (en) * 2024-01-31 2025-08-07 Tango Therapeutics, Inc. Crystalline forms, pharmaceutical compositions and methods of use thereof
WO2025171296A1 (en) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Ras inhibitors
WO2025217297A1 (en) * 2024-04-09 2025-10-16 Tango Therapeutics, Inc. Prmt5 inhibitors for use in methods of treating mta-accumulating cancer
WO2025240847A1 (en) 2024-05-17 2025-11-20 Revolution Medicines, Inc. Ras inhibitors
WO2025250569A1 (en) * 2024-05-29 2025-12-04 Amgen Inc. Cancer treatments using mta-cooperative prmt5 inhibitors and mat2a inhibitors
WO2025255438A1 (en) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2025265060A1 (en) 2024-06-21 2025-12-26 Revolution Medicines, Inc. Therapeutic compositions and methods for managing treatment-related effects
WO2026006747A1 (en) 2024-06-28 2026-01-02 Revolution Medicines, Inc. Ras inhibitors
WO2026015801A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015790A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015825A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Use of ras inhibitor for treating pancreatic cancer
WO2026015796A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026050446A1 (en) 2024-08-29 2026-03-05 Revolution Medicines, Inc. Ras inhibitors
WO2026072904A2 (en) 2024-09-26 2026-04-02 Revolution Medicines, Inc. Compositions and methods for treating lung cancer
WO2026090116A2 (en) 2024-10-21 2026-04-30 Revolution Medicines, Inc. Ras inhibitors
WO2026090245A1 (en) 2024-10-22 2026-04-30 Revolution Medicines, Inc. Use of ras inhibitors for treating cancer
US20260108528A1 (en) 2024-10-22 2026-04-23 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2018006781A (es) * 2015-12-03 2018-11-09 Agios Pharmaceuticals Inc Inhibidores de mat2a para el tratamiento del cancer que no expresen mtap.
MX2021006841A (es) * 2018-12-10 2021-07-02 Ideaya Biosciences Inc Derivados de 2-oxoquinazolina como inhibidores de metionina adenosiltransferasa 2?.
US11492351B2 (en) * 2019-09-12 2022-11-08 Mirati Therapeutics, Inc. MTA-cooperative PRMT5 inhibitors
CR20220175A (es) * 2019-10-22 2022-06-21 Lupin Ltd Combinación farmacéutica de inhibidores de PRMT5
WO2021086879A1 (en) * 2019-10-28 2021-05-06 Tango Therapeutics, Inc. Compounds and methods of use
KR20240019172A (ko) * 2021-06-02 2024-02-14 아이디어야 바이오사이언시스 인코포레이티드 Mat2a 억제제 및 유형 ii prmt 억제제를 포함하는 병용 요법

Also Published As

Publication number Publication date
EP4347569A4 (en) 2025-03-26
MX2023014405A (es) 2024-04-30
KR20240019172A (ko) 2024-02-14
CA3220160A1 (en) 2022-12-08
EP4347569A1 (en) 2024-04-10
WO2022256806A1 (en) 2022-12-08
CL2023003603A1 (es) 2024-07-12
BR112023025360A2 (pt) 2024-02-20
JP2024521920A (ja) 2024-06-04
US12115163B2 (en) 2024-10-15
US20240108626A1 (en) 2024-04-04
AU2022287057A1 (en) 2023-12-14
US20240173326A1 (en) 2024-05-30

Similar Documents

Publication Publication Date Title
US12115163B2 (en) Combination therapy comprising a MAT2A inhibitor and a type II PRMT inhibitor
US20240269143A1 (en) Combination therapy comprising a mat2a inhibitor and type i prmt inhibitor
US11084798B1 (en) 2-oxoquinazoline derivatives as methionine adenosyltransferase 2A inhibitors
US12084429B2 (en) Fused ring compounds
CN114456175B (zh) 作为tam抑制剂的吡咯并三嗪化合物
TW202304934A (zh) 非環氧氮呯化合物及其用途
EP2364302B1 (en) Triazine analogs and their use as therapeutic agents and diagnostic probes
KR102816365B1 (ko) 피라진 화합물 및 이의 용도
JP2022515198A (ja) FGFRチロシンキナーゼの阻害剤としての置換ピラゾロ[1,5-a]ピリジン化合物
JP7723666B2 (ja) 環式化合物およびその使用方法
US20180250400A1 (en) Therapeutic Combinations of a BTK Inhibitor, a PI3K Inhibitor, a JAK-2 Inhibitor, and/or a CDK4/6 Inhibitor
EP4334298A1 (en) Urea derivatives which can be used to treat cancer
EP1740184A1 (en) Combinations of signal transduction inhibitors
EP1942900A2 (en) Use of pyrazolo [1,5-a] pyrimidine derivatives for inhibiting kinases methods for inhibiting protein kinases
CA2921959A1 (en) Furo- and thieno-pyridine carboxamide compounds useful as pim kinase inhibitors
US20230133671A1 (en) Setd2 inhibitors and related methods and uses, including combination therapies
US20240299352A1 (en) Combination therapies with setd2 inhibitors
EP4558505A2 (en) Cyclic compounds and methods of using same
CN117440813A (zh) 治疗脑或cns的癌转移的egfr降解剂
JP7808616B2 (ja) 環式化合物及びそれを使用する方法
RU2809631C2 (ru) Пиразиновые соединения и их применения
JP2020537661A (ja) ピリミジンTBK/IKKεインヒビター化合物およびそれらの使用
WO2024227033A1 (en) Heterocyclic compounds as parp1 inhibitors
CN121752567A (zh) 用于抑制wee1 a激酶方法中的吡唑并嘧啶酮化合物
CA3259052A1 (en) HETEROCYCLIC COMPOUNDS USED AS PI3K.ALPHA INHIBITORS.